Kappa Opioid Antidepressant Navacaprant Goes 0-for-3 in Phase 3: Neumora Cuts 35% of Staff

Antidepressant clinical trial failure: Neumora Therapeutics killed navacaprant after three consecutive Phase 3 misses against placebo in 852 patients, dealing a major blow to kappa opioid receptor antagonism as a treatment for major depressive disorder — and leaving millions of treatment-resistant patients without a new option.